Systemic effects of conjugated equine estrogen vaginal cream on bone turnover markers in postmenopausal women

References

• Birkhäuser MH, Panay N, Archer DF, . Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2008;11:108–23
   PubMed Web of Science ®Google Scholar
• Rossin-Amar B. Vaginal dryness in the menopausal woman (physiological and psychological aspects). Gynecol Obstet Fertil 2000;28:245–9
   PubMedGoogle Scholar
• Berman JR, Berman LA, Werbin TJ, Goldstein I. Female sexual dysfunction: anatomy, physiology, evaluation and treatment options. Curr Opin Urol 1999;9:563–8
   PubMedGoogle Scholar
• American Society for Reproductive Medicine. Estrogen and progestogen therapy in postmenopausal women. Fertil Steril 2004;82(Suppl 1):S70–80
   PubMed Web of Science ®Google Scholar
• Ayton RA, Darling GM, Murkies AL, . A comparative study of safety and efficacy of continuous low-dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 1996;103:351–8
   PubMedGoogle Scholar
• Chompootaweep S, Nunthapisud P, Trivijitsilp P, Sentrakul P, Dusitsin N. The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study. Clin Pharmacol Ther 1998;64:204–10
   PubMed Web of Science ®Google Scholar
• Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178–80
   PubMed Web of Science ®Google Scholar
• Notelovitz M. Estrogen therapy in the management of problems associated with urogenital ageing: a simple diagnostic test and the effect of the route of hormone administration. Maturitas 1995;22(Suppl):S31–3
   PubMed Web of Science ®Google Scholar
• Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7:156–61
   PubMed Web of Science ®Google Scholar
• Handa VL, Bachus KE, Johnston WW, Robboy SJ, Hammond CB. Vaginal administration of low-dose conjugated estrogen; systemic absorption and effects on the endometrium. Obstet Gynecol 1994;84:215–18
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Ebert GA, Burd ID. Vulvovaginal complaints. In Lobo RA, ed. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. New York: Lippincott Williams & Wilkins, 1999:195–201
   Google Scholar
• Keenan NL, Franks AL, Croft JB, Scholes D, Murray ET. Vaginal estrogen creams: use patterns among a cohort of women. J Am Geriatr Soc 1999;47:65–70
   PubMed Web of Science ®Google Scholar
• Taechakraichana N, Intraragsakul A, Panyakhamlerd K, Numchaisrika P, Limpaphayom K. Estradiol and follicle-stimulating hormone levels in oophorectomized women using vaginal estrogen. J Med Assoc Thai 1997;80:626–30
   PubMedGoogle Scholar
• Labrie F, Cusan L, Gomez JL, . Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009;16:30–6
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Julía MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005;52(Suppl1):S46–52
   PubMed Web of Science ®Google Scholar
• Dogan E, Posaci C. Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women. Postgrad Med J 2002;78:727–31
   PubMed Web of Science ®Google Scholar
• Lewiecki EM. Prevention and treatment of postmenopausal osteoporosis. Obstet Gynecol Clin N Am 2008;35:301–15
   PubMed Web of Science ®Google Scholar
• Garnero P, Delmas PD. Biochemical markers of bone turnover: application for osteoporosis. Endocrinol Metab Clin N Am 1998;27:303–23
   PubMed Web of Science ®Google Scholar
• Reid IR, Eastell R, Fogelman I, . A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med 2004;164: 871–9
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int 2005;16:372–9
   PubMed Web of Science ®Google Scholar
• Kim JG, Kim JH, Lee DO, . Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor B ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women. Menopause 2008;15:357–62
   PubMed Web of Science ®Google Scholar
• Ausmanas MK, Holinka CF, Ling YF, Christiansen C. Effect of three doses of conjugated estrogens/medroxyprogesterone acetate on biomarkers of bone turnover and cartilage degradation in postmenopausal women: the Pan-Asia Menopause (PAM) study. Climacteric 2007;10:306–13
   PubMed Web of Science ®Google Scholar
• Rosen HN, Parker RA, Greenspan SL, . Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT. Calcif Tissue Int 2004;74:415–23
   PubMed Web of Science ®Google Scholar
• Tsai KS, Yen ML, Pan HA, . Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women. Osteoporos Int 2001;12:1020–5
   PubMed Web of Science ®Google Scholar
• Yasui T, Uemura H, Umino Y, . Undercarboxylated osteocalcin concentration in postmenopausal women receiving hormone therapy daily and on alternate days. Menopause 2006;13: 314–22
   PubMed Web of Science ®Google Scholar
• Warming L, Ravn P, Christiansen C. Levonorgestrel and 17-estradiol given transdermally for the prevention of postmenopausal osteoporosis. Maturitas 2005;50:78–85
   PubMed Web of Science ®Google Scholar
• García-Péres MA, Moreno-Mercer J, Tarín JJ, Cano A. Similar efficacy of low and standard doses of transdermal estradiol in controlling bone turnover in postmenopausal women. Gynecol Endocrinol 2006;22:179–84
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–22
   PubMed Web of Science ®Google Scholar
• Bachmann G. Urogenital ageing: an old problem newly recognized. Maturitas 1995;22:S1–5
   PubMed Web of Science ®Google Scholar
• Suckling JA, Kennedy R, Lethaby A, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Sys Rev 2006;(4):CD001500
   PubMed Web of Science ®Google Scholar
• Bjarnason NH, Christiansen C. Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone 2000;26:561–9
   PubMed Web of Science ®Google Scholar
• Pacifici R. The physiology of bone turnover. In Genant HK, Guglielmi G, Jergas M, eds. Bone Densitometry and Osteoporosis. Berlin: Springer, 1998:43–60
   Google Scholar
• Ringe JD. Pathophysiology of postmenopausal osteoporosis. In Rizzoli R, ed. Atlas of Postmenopausal Osteoporosis. London: Current Medicine Group, 2005:1–24
   Google Scholar
• Seibel MJ. Biochemical markers of bone turnover. I. Biochemistry and variability. Clin Biochem Rev 2005;26:97–122
   PubMedGoogle Scholar
• Mandel FP, Geola FL, Meldrum DR, . Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1983;57:133–9
   PubMed Web of Science ®Google Scholar
• Rosen CJ, Chesnut CH III, Mallinak NJ. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 1997;82:1904–10
   PubMed Web of Science ®Google Scholar
• Kenny AM, Prestwood KM, Biskup B, . Comparison of the effects of calcium loading with calcium citrate or calcium carbonate on bone turnover in postmenopausal women. Osteoporos Int 2004;15:290–4
   PubMed Web of Science ®Google Scholar
• Pongchaiyakul C, Kosulwat V, Charoenkiatkul S, Chailurkit LO, Rojroongwasinkul N, Rajatanavin R. The association of dietary calcium, bone mineral density and biochemical bone turnover markers in rural Thai women. J Med Assoc Thai 2008;91: 295–302
   PubMedGoogle Scholar
• Nititham S, Srianujata S, Rujirawat T. Dietary intake of phytate, zinc and calcium of self-selected diets of Ubon Ratchathani and Bangkok subjects, Thailand. J Med Assoc Thai 1999;82:855–61
   PubMedGoogle Scholar
• Howteerakul N, Suwannapong N, Sittilerd R, Rawdaree P. Health risk behaviours, awareness, treatment and control of hypertension among rural community people in Thailand. Asia Pac J Public Health 2006;18:3–9
   PubMed Web of Science ®Google Scholar
• Densupsoontorn N, Jirapinyo P, Thamonsiri N, Chantaratin S, Wongarn R. Lactose intolerance in Thai adults. J Med Assoc Thai 2004;87:1501–5
   PubMedGoogle Scholar
• Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Cummings SR. Association between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab 1998;83:2239–43
   PubMed Web of Science ®Google Scholar
• Bachmann G, Bouchard C, Hoppe D, . Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause 2009;16:719–27
   PubMed Web of Science ®Google Scholar